Navigation Links
Bunge Reports Fourth Quarter Net Income of $245 Million
Date:2/7/2008

reholders $230 $260 (12)% $738 $517 43%

Earnings per common

share - diluted

(Note 1): $1.82 $2.12 (14)% $5.95 $4.28 39%

Weighted-average

common shares

outstanding

-diluted

(Note 1) 134,501,104 124,409,362 130,753,807 120,849,357

Note 1: The dilutive effect of the of 11,661,359 and 8,536,729 weighted

average common shares, which would be issuable upon conversion of

Bunge's convertible preference shares, is included in the

earnings per common share - diluted calculation for the quarter

and year ended December 31, 2007, respectively, because the

effect of the conversion would have been dilutive.

CONSOLIDATED SEGMENT INFORMATION

(In millions, except volumes and percentages)

(Unaudited) (Note 1 and 2)

Set forth below is a summary of certain items in our consolidated

statements of income and volumes by reportable segment.

Quarter Ended Year Ended

December 31, Percent December 31, Percent

2007 2006 Change 2007 2006 Change

Volumes (in thousands

of metric tons):

Agribusiness 28,104 24,645 14% 114,365 99,801 15%

Fertilizer 3,548 3,921 (10)% 13,077 11,578 13%

Edible oil products 1,461 1,266 15% 5,530 4,777 16%

Milling products 973 933 4% 3,983 3,895 2%

Total 34,086 30,765 11% 136,955 120,051 14%

Net sales:

Agribusiness $10,481 $5,471 92% $33,877 $18,909 79%

Fertilizer 1,280 918 39% 3,944 2,602 52%

Edible oil products 1,840 1,043 76% 5,622 3,798 48%

Milling prod
'/>"/>

SOURCE Bunge Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Recent Research Reports and Near-Term Corporate Events
5. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
6. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
7. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
8. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
11. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... equipment, to creating professional commercial video content, to analysis of athletic performance. Producing ... events that go by too quickly to process with the naked eye. ...
(Date:9/1/2015)...  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... Global Investment Conference sponsored by H.C. Wainwright ... St. Regis Hotel in New York, NY ... Chief Executive Officer, will provide an overview of the ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... , ... ... ... ...
... ... ... ... ...
... , ... for Rare Disease Day, hopes to bring more attention to the need for finding more ... ... hopes to draw more attention to the urgent need of finding more treatments for rare ...
Cached Biology Technology:Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO 2Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO 3Merck KGaA and Millipore Announce Transaction - Video Interview with Merck CEO 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 2Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 5Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 6Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 7Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day 2
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... a molecule on the surface of B cells, a finding ... insidious attack on the immune system, University of Pittsburgh researchers ... , "The research supports a new role for B cells ... important implications for future studies and drug development efforts that ...
... "off" switch packaged in a tiny sphere penetrates deeply ... and drastically reducing the size of tumors, researchers at ... report in the Aug. 15 edition of Clinical Cancer ... cover of the journal, demonstrates a potent delivery system ...
... reported this week reveal that at least some primates can ... for guiding their foraging behavior when searching for ripening fruit. ... skills developed in humans and other primates, is reported by ... of St. Andrews in the June 20th issue of Current ...
Cached Biology News:HIV infection requires an accomplice: B cells with special protein direct HIV to T cells 2Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial 2Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial 3Primates take weather into account when searching for fruits 2
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Request Info...
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
Biology Products: